Medical - Distribution
Compare Stocks
5 / 10Stock Comparison
RDGT vs DBVT vs ALKS vs PRGO vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
RDGT vs DBVT vs ALKS vs PRGO vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Distribution | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $382.00 | $1712.35T | $5.90B | $1.61B | $41.93B |
| Revenue (TTM) | $259M | $0.00 | $1.56B | $4.18B | $17.35B |
| Net Income (TTM) | $7M | $-168M | $153M | $-1.82B | $1.56B |
| Gross Margin | 8.3% | — | 65.4% | 34.2% | 52.1% |
| Operating Margin | -1.8% | — | 12.3% | -4.1% | 13.2% |
| Forward P/E | — | — | 24.8x | 5.6x | 14.5x |
| Total Debt | $10M | $22M | $70M | $3.97B | $17.38B |
| Cash & Equiv. | $13M | $194M | $1.12B | $532M | $3.56B |
RDGT vs DBVT vs ALKS vs PRGO vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Ridgetech Inc. (RDGT) | 100 | 0.0 | -100.0% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RDGT vs DBVT vs ALKS vs PRGO vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RDGT ranks third and is worth considering specifically for efficiency.
- 8.7% ROA vs DBVT's -89.0%
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs RDGT's -99.1%
ALKS has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.
- -11.0% 10Y total return vs TEVA's -28.3%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
- 9.8% margin vs PRGO's -43.5%
PRGO is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Lower P/E (5.6x vs 14.5x)
- 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend
TEVA is the clearest fit if your priority is growth exposure.
- Rev growth 4.3%, EPS growth 182.8%, 3Y rev CAGR 5.0%
- 4.3% revenue growth vs DBVT's -100.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.3% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (5.6x vs 14.5x) | |
| Quality / Margins | 9.8% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 1.06 vs DBVT's 1.26, lower leverage | |
| Dividends | 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs RDGT's -99.1% | |
| Efficiency (ROA) | 8.7% ROA vs DBVT's -89.0% |
RDGT vs DBVT vs ALKS vs PRGO vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
RDGT vs DBVT vs ALKS vs PRGO vs TEVA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 3 of 6 categories
RDGT leads 1 • TEVA leads 1 • PRGO leads 1 • DBVT leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA and DBVT operate at a comparable scale, with $17.3B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $259M | $0 | $1.6B | $4.2B | $17.3B |
| EBITDAEarnings before interest/tax | $2M | -$112M | $212M | $58M | $3.3B |
| Net IncomeAfter-tax profit | $7M | -$168M | $153M | -$1.8B | $1.6B |
| Free Cash FlowCash after capex | -$10M | -$151M | $392M | $108M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +8.3% | — | +65.4% | +34.2% | +52.1% |
| Operating MarginEBIT ÷ Revenue | -1.8% | — | +12.3% | -4.1% | +13.2% |
| Net MarginNet income ÷ Revenue | +2.6% | — | +9.8% | -43.5% | +9.0% |
| FCF MarginFCF ÷ Revenue | -3.7% | — | +25.1% | +2.6% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -11.7% | — | +28.2% | -7.2% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +97.5% | +91.5% | -4.1% | -56.4% | +72.2% |
Valuation Metrics
RDGT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ALKS trades at a 18% valuation discount to TEVA's 30.0x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than TEVA's 17.6x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $382 | $1712.35T | $5.9B | $1.6B | $41.9B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $1712.35T | $4.9B | $5.1B | $55.8B |
| Trailing P/EPrice ÷ TTM EPS | 0.00x | -0.76x | 24.76x | -1.14x | 30.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 5.56x | 14.55x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | -0.48x | — | 17.25x | 7.42x | 17.65x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — | 4.00x | 0.38x | 2.43x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.66x | 3.28x | 0.55x | 5.34x |
| Price / FCFMarket cap ÷ FCF | 0.00x | — | 12.28x | 11.12x | 36.52x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
RDGT delivers a 29.1% return on equity — every $100 of shareholder capital generates $29 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +29.1% | -130.2% | +8.8% | -50.7% | +20.7% |
| ROA (TTM)Return on assets | +8.7% | -89.0% | +5.4% | -19.8% | +3.9% |
| ROICReturn on invested capital | -2.4% | — | +18.9% | +3.7% | +7.7% |
| ROCEReturn on capital employed | -4.1% | -145.7% | +14.2% | +4.3% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 4 | 8 |
| Debt / EquityFinancial leverage | 0.35x | 0.13x | 0.04x | 1.35x | 2.20x |
| Net DebtTotal debt minus cash | -$2M | -$172M | -$1.0B | $3.4B | $13.8B |
| Cash & Equiv.Liquid assets | $13M | $194M | $1.1B | $532M | $3.6B |
| Total DebtShort + long-term debt | $10M | $22M | $70M | $4.0B | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x | 32.30x | -7.20x | 2.51x |
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $0 for RDGT. Over the past 12 months, DBVT leads with a +110.4% total return vs RDGT's -99.1%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs RDGT's -91.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -99.6% | +4.9% | +25.3% | -13.5% | +16.3% |
| 1-Year ReturnPast 12 months | -99.1% | +110.4% | +16.5% | -51.2% | +104.6% |
| 3-Year ReturnCumulative with dividends | -99.9% | +19.7% | +14.5% | -58.1% | +297.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | -69.1% | +60.9% | -60.1% | +246.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% | -11.0% | -77.7% | -28.3% |
| CAGR (3Y)Annualised 3-year return | -91.6% | +6.2% | +4.6% | -25.2% | +58.4% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs RDGT's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.26x | 1.06x | 1.18x | 1.13x |
| 52-Week HighHighest price in past year | $760.50 | $26.18 | $36.60 | $28.44 | $37.35 |
| 52-Week LowLowest price in past year | $1.23 | $7.53 | $25.17 | $9.23 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +76.3% | +96.7% | +41.2% | +96.4% |
| RSI (14)Momentum oscillator 0–100 | 32.8 | 48.1 | 60.2 | 60.9 | 73.5 |
| Avg Volume (50D)Average daily shares traded | 59.4M | 252K | 2.3M | 3.4M | 6.6M |
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy", PRGO as "Hold", TEVA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 8.3% for TEVA (target: $39). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $44.00 | $20.00 | $39.00 |
| # AnalystsCovering analysts | — | 15 | 28 | 36 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | 10 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% | 0.0% |
ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RDGT leads in 1 (Valuation Metrics).
RDGT vs DBVT vs ALKS vs PRGO vs TEVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RDGT or DBVT or ALKS or PRGO or TEVA a better buy right now?
For growth investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger pick with 4.
3% revenue growth year-over-year, versus -22. 4% for Ridgetech Inc. (RDGT). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RDGT or DBVT or ALKS or PRGO or TEVA?
On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.
8x versus Teva Pharmaceutical Industries Limited at 30. 0x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RDGT or DBVT or ALKS or PRGO or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to -100. 0% for Ridgetech Inc. (RDGT). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus RDGT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RDGT or DBVT or ALKS or PRGO or TEVA?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 19% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — RDGT or DBVT or ALKS or PRGO or TEVA?
By revenue growth (latest reported year), Teva Pharmaceutical Industries Limited (TEVA) is pulling ahead at 4.
3% versus -22. 4% for Ridgetech Inc. (RDGT). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RDGT or DBVT or ALKS or PRGO or TEVA?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -0. 9% for RDGT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RDGT or DBVT or ALKS or PRGO or TEVA more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — RDGT or DBVT or ALKS or PRGO or TEVA?
In this comparison, PRGO (9.
8% yield) pays a dividend. RDGT, DBVT, ALKS, TEVA do not pay a meaningful dividend and should not be held primarily for income.
09Is RDGT or DBVT or ALKS or PRGO or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RDGT and DBVT and ALKS and PRGO and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RDGT is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; TEVA is a mid-cap quality compounder stock. PRGO pays a dividend while RDGT, DBVT, ALKS, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.